© V. S. Soultanov 1, V.I. Roshchin2, V.G. Agishev 3, I.S. Monakhova 3, K. P. Kulikov 3, T. V. Nikitina 4
1 Solagran Limited, Melbourne, Australia
2 Kirov Forest Technical Academy, Saint-Petersburg
3 Skvortsov-Stepanov Psychiatric Hospital, Saint -Petersburg
4 Sechenov Institute of Evolutionary Physiology and Biochemistry of Russian Academy of Sciences, Saint -Petersburg
Introduction. The Alzheimer’s disease is the root cause for senile dementia of middle-aged and elderly people in developed countries. As human civilization grows older and duration of life increases the Alzheimer’s disease is becoming a serious problem. The regulation of acetylcholine level is supposed to be done by by butyrylcholin esterase BTL, the presence of which was revealed in senile plaques, fibrillar glomerules and vascular walls (amyloid angiopathy) along with acetylcholinesterase enzyme, the deficit of which is observed in Alzheimer’s disease. The deficit of adrenergic impulses in Alzheimer’s disease directly correlates with development and manifestation of depression that leads to three-times increase of monoamine oxidase (MAO).
For reasons given the world medical community is in search of a double –acting preparation – inhibitors of acetylcholinesterase and BCHE, and also inhibitors of acetylcholinesterase and MAO for treatment of Alzheimer’s disease. Search of new pharmaceuticals with minimum side effects is an actual problem for treatment of different neurodegenerative diseases as synthesized substances are toxic and can’t be used for a long time.
The purpose of research was studying of the effect polyprenol preparation derived from green needles produces in treatment of dementias of the Alzheimer’s type along with vascular cerebral affection.
Methods. The clinical trial was conducted with 25 patients at the age of 54-78 on the bases of the Skvortsov-Stepanov Psychiatric Hospital ¡í 3. The average duration of the disease is 1,5 years. The course of treatment was 3-4 months. Polyprenols were given in a dose of 144 mg a day. Somatic therapy was used in the period of treatment. International scale of cognitive deficit MMSE, unified rating scale of Parkinson's disease, EEG data, biochemical blood values, urine analysis, activity of BCHE and monoamine oxidase (MAO). The preparation was given to the patients during 4 months. Before the treatment 12% patients had a light form of dementia, 36% — moderately marked, 32% — moderately serious, 20% — severe dementia.
Research results showed the effectiveness of polyprenol action on cognitive functions: 40% patients had marked improvement of cognitive functions. 48% patients had less marked effect in psychosomatic status, but a positive dynamics in the degree of manifestation of dementia, which reduced coming from severe form to a light form. 12% patients taking polyprenols didn’t have any improvement of cognitive function. According to EEG the condition of 80% patients improved that was shown by disappearance delta waves and paroxysms, onset of ¨»-rhythm and disappearance of local accent in frontotemporal area. Polyprenol preparation produces normalizing effect on the activity of BCHE and monoamine oxidase (MAO) of blood serum. 25% patients had improvement of neurological status, there was 5 points reduce in Parkinson's syndrome according to parkinsonism scale in a month of treatment that is a good prognostic factor in the treatment of the disease.
Conclusion. On the basis of the information received it was concluded that polyprenol preparation can be used for treatment of neurodegenerative diseases of the Alzheimer’s type.